Inhibition of PCSK9 does not improve lipopolysaccharide-induced mortality in mice

Inhibition of PCSK9 does not improve lipopolysaccharide-induced mortality in mice

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secreted protein that targets LDL receptors (LDLRs) for degradation in liver. Blocking the interaction of PCSK9 with the LDLR potently reduces plasma LDL cholesterol levels and cardiovascular events. Recently, it has been suggested that inhi...

Full description

Bibliographic Details
Main Authors: Jean-Mathieu Berger, Angel Loza Valdes, Jesper Gromada, Norma Anderson, Jay D. Horton
Format: Article
Language:English
Published: Elsevier 2017-08-01
Series:Journal of Lipid Research
Subjects:
lipopolysaccharide
endotoxemia
cholesterol
LDL
PCSK9
Online Access:http://www.sciencedirect.com/science/article/pii/S0022227520337913

Similar Items

Similar Items